MaryRose Reaston is the founder of Emerge Diagnostics, a company created to commercialize the electrodiagnostic functional assessment (EFA). Emerge Diagnostics focuses on reducing clients’ claims costs via early resolution and enhanced treatment options for soft-tissue injuries. The EFA uses a proprietary, FDA-cleared, 510K Class-II medical device designed to evaluate and monitor musculoskeletal injuries.
Baseline testing allows the best appropriation of resources in private healthcare and workers’ compensation by objectively qualifying soft-tissue injuries. The EFA-STM is an example of an objective baseline test that has assisted with proper allocation of resources, thereby providing better treatment and outcomes.
Emerge Diagnostics focuses on reducing clients’ claims costs via early resolution and enhanced treatment options for soft-tissue injuries. The company is expert in the field of electrodiagnostic medicine as it applies to injuries in the workplace and is a leader in the continuing development of innovative technology.
Reaston has been instrumental in the development, commercialization, marketing and governmental acceptance of electrodiagnostic testing and has been classified in federal court as an expert witness in the area of electrodiagnostic techniques and evaluations. She has published articles on EFA in the Journal of Occupational Medicine and Technology, IEEE, is the holder of several patents and won the 2012 Risk Innovator of the Year award and the Liberty Mutual Responsibility Leader award from Risk & Insurance magazine for the EFA-STM program. She has testified before OSHA and Congress on the EFA.